PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL)
Clinical trials for PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL) explained in plain language.
Never miss a new study
Get alerted when new PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL) trials appear
Sign up with your email to follow new studies for PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
First-in-Human trial launches 'Double-Target' cell therapy for tough lymphomas
Disease control Recruiting nowThis is a first-in-human study testing a new type of personalized cell therapy called CD79b-19 CAR T cells for adults with Non-Hodgkin Lymphoma that has come back or not responded to prior treatments. The main goal is to find a safe dose of these modified immune cells, which are …
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL)
Phase: PHASE1 • Sponsor: Marcela V. Maus, M.D.,Ph.D. • Aim: Disease control
Last updated Apr 03, 2026 21:26 UTC
-
New 'Living Drug' trial offers hope for lymphoma patients out of options
Disease control Recruiting nowThis is a first-in-human study testing the safety and early effectiveness of a new, single-infusion CAR-T cell therapy called SynKIR-310. It is for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior treatments, including other CAR-T …
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL)
Phase: PHASE1 • Sponsor: Verismo Therapeutics • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
New CAR-T therapy trial offers hope for lymphoma patients who have run out of options
Disease control Recruiting nowThis study is testing a new type of personalized immune cell therapy called TC011 in adults whose large B-cell lymphoma has come back or hasn't responded to standard treatments. Doctors will collect a patient's own T-cells, genetically modify them in a lab to target cancer, and i…
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL)
Phase: PHASE1, PHASE2 • Sponsor: TICAROS Co., Ltd. • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
Scientists test 'Ready-Made' immune cell therapy for tough blood cancers
Disease control Recruiting nowThis early-stage study is testing the safety of a new type of cancer treatment called P-CD19CD20-ALLO1 in adults with specific B-cell lymphomas that have come back or not responded to standard therapies. The treatment involves giving patients a single infusion of specially engine…
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL)
Phase: PHASE1 • Sponsor: Poseida Therapeutics, Inc. • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
New 'Living Drug' trial offers hope for tough blood cancers
Disease control Recruiting nowThis is a first-in-human study testing a new personalized cell therapy called CLIC-2201 for adults and children with B-cell blood cancers that have returned or not responded to other treatments. The therapy involves collecting a patient's own immune cells, genetically modifying t…
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL)
Phase: PHASE1 • Sponsor: British Columbia Cancer Agency • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC
-
New hope for Tough-to-Treat lymphoma: trial tests Next-Gen cell therapy
Disease control Recruiting nowThis trial is testing a new, experimental CAR-T cell therapy called WZTL-002 for people with aggressive large B-cell lymphoma that has returned or not responded to standard chemotherapy. The main goals are to see how well the therapy works to eliminate the cancer and to understan…
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL)
Phase: PHASE2 • Sponsor: Malaghan Institute of Medical Research • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
Two-Pronged attack: new cell therapy aims to outsmart resistant blood cancers
Disease control Recruiting nowThis study is testing a new type of personalized cell therapy for adults whose B-cell blood cancers have come back or not responded to standard treatments. The therapy, called CAR-T, is engineered to attack cancer cells using two targets (CD19 and CD20) instead of one, which may …
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL)
Phase: PHASE1, PHASE2 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
New 'Off-the-Shelf' gene therapy aims to outsmart tough blood cancers
Disease control Recruiting nowThis early-stage study is testing a new, one-time gene therapy called VNX-101 for patients whose B-cell blood cancers have returned or not responded to other treatments. The therapy is designed to help the patient's own immune system continuously fight cancer cells. Researchers w…
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL)
Phase: PHASE1, PHASE2 • Sponsor: Vironexis Biotherapeutics Inc. • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
Tracking 'Living Drug' cells to improve cancer treatment
Disease control Recruiting nowThis study aims to better understand how CAR-T cell therapy works in patients with specific blood cancers (lymphoma and leukemia) in real-world settings. Researchers will closely monitor how long the modified immune cells last in the body and how well they fight the cancer. They …
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL)
Sponsor: Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC
-
New Two-Pronged attack tested for Tough-to-Treat lymphoma
Disease control Recruiting nowThis study is testing whether combining two powerful cancer treatments—CAR-T cell therapy and the drug pembrolizumab—works better than either alone for a type of lymphoma that has returned or not responded to prior treatments. About 35 adults with relapsed or refractory primary m…
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL)
Phase: PHASE2 • Sponsor: Jennifer Crombie, MD • Aim: Disease control
Last updated Mar 10, 2026 12:52 UTC
-
Can a 6-Month health plan boost life after lymphoma?
Symptom relief Recruiting nowThis study is testing whether a 6-month personalized health plan can improve the quality of life for people who survived lymphoma. The plan includes nutrition advice, physical activity guidance, and follow-up care. Researchers will compare the results of participants who follow t…
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL)
Phase: NA • Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Symptom relief
Last updated Mar 02, 2026 15:25 UTC